Conceptual view of short and longer RNA cargos in lipid nanoparticles. The study suggests that cargo size belongs in formulation screening; the artwork does not depict measured LC-1 structure.
The signal
A Nature Biotechnology study brings the screening payload into lipid discovery. Dong and colleagues screened 384 ionizable lipids using a 5.7-kb adenine-base-editor–NanoLuc reporter mRNA and identified LC-1 as a lead for large cargo. In the official abstract, the authors report up to 79% Cas9-mediated knockout in liver, 48% in brain and 27% in lung in mice after intravenous, intrathecal and intratracheal administration, respectively—up to fourfold higher than LP-01 and ALC-0315. These are author-reported, route- and model-specific peak results, not human efficacy or evidence that one intravenous formulation reaches all three organs.
Why the payload matters
A short reporter is convenient for screening, but a formulation selected with it still needs confirmation with the intended cargo. Supplementary Figs. 1–2 describe approximately 1.7-kb Fluc and 5.7-kb ABE–NanoLuc constructs. Their sequence and reporter systems differ along with length. This supports checking payload representativeness; it does not isolate length as the sole cause of a performance difference.
The supplementary material compares LC-1 with LP-01 and ALC-0315 formulations using particle characterization and delivery assays. Those measurements can help explain why similar-looking particles need not perform identically. They do not establish that one lipid is best across therapeutic sequences, doses and manufacturing processes.
A plausible mechanism, with a boundary
Supplementary Figs. 62–65 include endosomal-disruption, pH-dependent membrane-disruption and internal-structure measurements. These are useful mechanistic clues. A developer would still need to connect such measurements to product-specific expression or editing; a structural signature is not a validated potency surrogate by itself.
What changes for a developer?
For a small team selecting a lipid or a CDMO formulation, we would first ask whether its screening cargo represents the intended product. A useful bridge compares the existing reporter with a representative product construct under defined RNA dose and formulation conditions, measuring expression or editing alongside RNA integrity, encapsulation and particle attributes. If the question is specifically about length, the design also needs to control sequence and reporter effects.
Route is another part of that bridge. The supplement includes intravenous, intrathecal and intratracheal mouse experiments; these expose particles to different biological environments. Results after local brain or lung administration cannot establish systemic access to those tissues. Target-cell coverage, exposure and tolerability need confirmation for the proposed product and route.
The CMC question is whether a promising formulation can be made reproducibly. A new lipid brings sourcing, identity and impurity-control work; larger RNA adds questions about intact transcript fraction, recovery, mixing and potency. Supplementary Figs. 66–67 track diameter and PDI over 14 days, while Figs. 99–101 provide small-group immune and repeat-administration readouts. These are useful early data. Particle-size stability cannot substitute for RNA and potency stability, and nonsignificant immune differences do not establish safety equivalence.
RapidGene view
Our practical takeaway is to confirm the screening result with cargo that reflects the intended medicine before committing to a formulation. For an established program, this argues for a product-specific bridging comparison, not an automatic switch to LC-1. A switch must earn its place through potency, safety, process and access evidence.
What to watch
Watch for independent testing across additional RNA sequences, comparisons that separate length from sequence and assay effects, product-specific stability and repeat-dose evidence, and manufacturing-scale comparability. The authors disclose an invention covering the lipids, so access and freedom to operate require separate diligence.
Source
Dong S, Gong F, Thomson T, et al. Lipid nanoparticles optimized for large RNA cargo and tissue targeting enhance in vivo genome editing. Nature Biotechnology. DOI: 10.1038/s41587-026-03298-8. https://www.nature.com/articles/s41587-026-03298-8
Review scope: this short analysis cites the official abstract for the reported peak results and draws on checked supplementary figures/tables for development context. The subscription main text was not reviewed; the peak results are not an independent methods-level validation by RapidGene.
Nature Biotechnology Research Briefing: https://www.nature.com/articles/s41587-026-03297-9
Supplementary information (publisher; 101 figures, 5 tables): https://media.springernature.com/original/springer-static/esm/art%3A10.1038%2Fs41587-026-03298-8/MediaObjects/41587_2026_3298_MOESM1_ESM.pdf